The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Canceropen access
- Authors
- Kang, Ho Won; Jung, Hae Do; Lee, Joo Yong; Kwon, Jong Kyou; Jeh, Seong Uk; Cho, Kang Su; Ham, Won Sik; Choi, Young Deuk
- Issue Date
- Jan-2018
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Prostate-specific Antigen; Prostate-specific Antigen Density; Prostatic Neoplasms; Prostatectomy; Biochemical Recurrence
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.33, no.5
- Indexed
- SCI
SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 33
- Number
- 5
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/12052
- DOI
- 10.3346/jkms.2018.33.e36
- ISSN
- 1011-8934
1598-6357
- Abstract
- Background: Significant clinical heterogeneity within contemporary risk group is well known, particularly for those with intermediate-risk prostate cancer (IRPCa). Our study aimed to analyze the ability of the Cancer of the Prostate Risk Assessment (CAPRA) score to discern between favorable and non-favorable risk in patients with IRPCa. Methods: We retrospectively reviewed the data of 203 IRPCa patients who underwent extraperitoneal robot-assisted radical prostatectomy (RARP) performed by a single surgeon. Pathologic favorable IRPCa was defined as a Gleason score <= 6 and organ-confined stage at surgical pathology. The CAPRA score was compared with two established criteria for the within-group discrimination ability. Results: Overall, 38 patients (18.7% of the IRPCa cohort) had favorable pathologic features after RARP. The CAPRA score significantly correlated with established criteria I and II and was inversely associated with favorable pathology (all P < 0.001). The area under the receiver operating characteristic curve for the discriminative ability between favorable and non-favorable pathology was 0.679 for the CAPRA score and 0.610 and 0.661 for established criteria I and II, respectively. During a median 37.8 (interquartile range, 24.6-60.2) months of follow-up, 66 patients (32.5%) experienced biochemical recurrence (BCR). Cox regression analysis revealed that the CAPRA score, as a continuous sum score model or 3-group risk model, was an independent predictor of BCR after RARP. Conclusion: The within-group discrimination ability of preoperative CAPRA score might help in patient counseling and selecting optimal treatments for those with IRPCa.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.